{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigpd43u4qhuu73zvqdljvmvojuc53n4winij36tvgwoauusyhgwva",
    "uri": "at://did:plc:wwyqal4cnqhuwyacdj7rqq3n/app.bsky.feed.post/3mijs5onqki62"
  },
  "path": "/t/collider-in-rct-subgroup-analysis/28689#post_3",
  "publishedAt": "2026-04-02T07:14:37.000Z",
  "site": "https://discourse.datamethods.org",
  "tags": [
    "here"
  ],
  "textContent": "Pavlos_Msaouel:\n\n> See also here.\n\nThis was extremely helpful! I have a clarification question: In the example you give, if EGFR mutation was the **only** cause of oncogenic EGFR, would we still get a biased estimate in a subgroup of patients with oncogenic EGFR signaling? I would think not as in this instance this would be equivalent to an RCT in patients with EGFR mutation, would it not?\n\nI’m also somewhat confused by the treatment indicator **causing** EGFR signaling. Temporally, I would assume EGFR signaling to already be present / absent before randomization (?) .",
  "title": "Collider in RCT Subgroup Analysis"
}